TO

Oncology Institute IncNASDAQ TOI Stock Report

Last reporting period 30 Jun, 2024

Updated 14 Nov, 2024

Last price

Market cap $B

0.022

Micro

Exchange

XNAS - Nasdaq

TOI Stock Analysis

TO

Uncovered

Oncology Institute Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-44/100

Low score

Market cap $B

0.022

Dividend yield

Shares outstanding

74.552 B

The Oncology Institute, Inc. provides cancer care treatment services. The company is headquartered in Cerritos, California. The company went IPO on 2020-03-13. The firm manages community-based oncology practices that serve patients at approximately 67 clinic locations across 11 markets and four states throughout the United States. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, and dispensary, clinical trial services, radiation, programs like outpatient stem cell transplants and transfusions, along with 24/7 patient support. The company offers cutting-edge treatment through clinical trials. The company also offers convenient, safe appointments via telehealth. The firm through Innovative Clinical Research Institute, LLC (ICRI), provides and manages clinical trial services and research for the benefit of cancer patients. The firm's segment includes patient care, dispensary, and clinical trials & other. Its managed clinics primarily serve adult and senior cancer patients in markets that have Medicare Advantage (MA) plans.

View Section: Eyestock Rating